Full-Time

Senior Supply Planner

Posted on 6/4/2025

Stryker

Stryker

10,001+ employees

Manufactures orthopedic and surgical medical devices

Compensation Overview

$77.2k - $160.8k/yr

+ Bonus + Benefits

Company Historically Provides H1B Sponsorship

Redmond, WA, USA

Hybrid

Bachelor's

Category
Operations & Logistics (1)
Required Skills
Inventory Management

Get referred to Stryker

See people who can refer or advise you

Requirements
  • Bachelor’s degree - highly preferred; or in lieu of a degree, 6 years of equivalent experience will be considered in addition to the experience below
  • 4+ years of post-graduate professional experience - required
  • APICS accredited or professional supply chain accreditation preferred
  • IT Planning system experience
  • Master data maintenance experience on ERP platforms and use of heuristics in driving exception based planning approach
  • Ability to demonstrate Project Management experience in running projects specifically around problem solving and root causing based on lean way of working (six sigma)
  • Experience of IBP and S&OP principles and demonstrate knowledge of the process in daily working within existing or previous business
Responsibilities
  • Responsible for the creation of a Master Resource Plan based on the latest demand signal to cover what needs to be produced or purchased as a finished product and to ensure that within the process there is sufficient raw materials and components to support the required supply plan up to a 24-month time horizon
  • Responsible for the creation of capacity plans based on the latest demand signal, to identify where there is any potential bottlenecks or risks to supply and to develop and recommend appropriate proposals to mitigate and to ensure that the plant or 3rd party can meet the future demand. Also identify where there is significant underutilization which could impact the costs of supply
  • Develop a supply plan across a complex portfolio and multiple sites if required as franchise maturity develops
  • Ability to work on capability building as part of cross functional teams and add expertise in creating the optimal solutions
  • Responsible for the setting of the correct levels of inventory within the supply plan by understanding the demand volatility and supply chain lead times. Specifically, the creation of a safety stock strategy and plan that enables continuity of product availability at the optimal level of cash investment
  • Ensure that the supply plan is financially evaluated with regard to balancing the requirement of consistent product availability versus the cost of supply and the investment needed in conjunction with financial partners to ensure meeting the operational budgets and targets
  • Track the execution of the supply plan with production scheduling and buying ensuring that the plan is fully operationalized and tracked for performance deviation including mitigation on back orders and pro-active communication of future supply risks
  • Ensure within the supply plan that products are being phased in and planned correctly as well as ensuring communication and timing of exiting products within the plant or 3rd party. Communicating with the business in regard to the status of the product portfolio from a supply planning perspective
  • Have effective communication and confirmation back from supply planning to the demand plan in confirming capability to meet the requirements via the daily and weekly execution process but also via a robust monthly executive supply process
  • KPIs for the role will be Supply Plan Attainment, Safety Stock Health, Capacity Utilization, Back order and Lead time
  • Responsible for root causing performance issues and acting on own capability to mitigate and correct
Desired Qualifications
  • APICS accredited or professional supply chain accreditation preferred

Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kalamazoo, Michigan

Founded

1941

Get referred to Stryker

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 organic sales rose 9%, with strong MedSurg and Orthopaedics growth.
  • AVS closed in Q2 2026, expanding peripheral vascular exposure and salesforce leverage.
  • Management raised 2026 outlook to 8.3%-9.3% organic growth and $14.95-$15.10 EPS.

What critics are saying

  • March 2026 cyberattack disrupted manufacturing, delayed shipments, and exposed operational fragility.
  • Peripheral vascular supply disruption created Q2 2026 backorders, with recovery targeted only by Q3.
  • Any repeat cyber incident or plant outage would hit revenue and threaten 2026 guidance.

What makes Stryker unique

  • Mako robotics keeps winning installations and supports Stryker's orthopedic workflow lock-in.
  • Stryker spans MedSurg, Neurotechnology, and Orthopaedics, cushioning demand across procedure types.
  • Pangea Plating and TPX HD show a steady, surgeon-led product launch cadence.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical & prescription plans

Supplemental health benefits

Flexible Spending accounts

Employee Assistance Program

Short-term & long-term disability

Tuition reimbursement

401(k) plan

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 2nd, 2026
Stryker shares drop 6.4% after Q2 earnings as analysts see 23% upside to $386.80 fair value

Stryker shares fell 6.42% following its second-quarter 2026 earnings release, which showed sales of $6.59 billion and net income of $1.28 billion. The medical technology company is now trading approximately 23% below one valuation estimate and 18% beneath the average analyst target. Analysts currently place Stryker's fair value at $386.80, compared to its recent closing price of $325.70. Price targets vary significantly amongst analysts, ranging from $315 to $465. The year-to-date share price return has fallen 6.46%, though the company maintains a five-year total shareholder return of 30.66%. Potential risks to the company's outlook include prolonged EU regulatory delays and sustained supply chain disruptions that could affect product launches and margins.

Yahoo Finance
Aug 1st, 2026
Stryker meets Q2 revenue expectations at $6.59B but supply chain woes dampen growth outlook

Stryker reported Q2 revenue of $6.59 billion, up 9.4% year on year, meeting Wall Street expectations. The medical technology company's non-GAAP earnings of $3.69 per share beat analyst estimates by 5.8%. Despite meeting forecasts, investors reacted negatively due to supply chain disruptions in the peripheral vascular business. Chief executive Kevin Lobo said the quarter focused on recovery from a recent cybersecurity incident, which caused production disruptions and elevated backlogs. The company expects backorders to normalise by the end of Q3. Management cited strong demand for capital equipment and Mako robotics, which saw record Q2 installations. Operating margin expanded to 25.2% from 18.5% last year, supported by operational discipline and efficiency initiatives. Management slightly raised full-year adjusted earnings guidance.

Yahoo Finance
Jul 31st, 2026
Stryker reports 9% organic sales growth in Q2 2026 despite cybersecurity impact

Stryker reported strong second-quarter 2026 results with 9% organic sales growth, driven by high single-digit gains in both its med surg and neurotechnology and orthopaedics businesses. The medical device company is recovering from a cybersecurity incident whilst ramping up production to meet demand. In the US, Stryker achieved 9% organic sales growth, with double-digit expansion in its medical, trauma extremities, and endoscopy divisions. The company's OrthoTech and instruments segments posted high single-digit growth. However, supply disruptions affected the peripheral vascular business, creating a significant backorder situation and lost sales. Stryker expects to resolve these issues by the end of the third quarter. The company also completed its acquisition of AVS during the quarter and remains confident in the long-term outlook for its peripheral vascular business.

Yahoo Finance
Jul 30th, 2026
Stryker reports $6.6B Q2 sales, up 9.4%, as company recovers from cyber incident

Stryker Corporation reported second quarter 2026 results, with net sales rising 9.4% to $6.6 billion and organic sales up 9.0%. The medical technology company's adjusted earnings per share increased 17.9% to $3.69, whilst reported EPS jumped 44.1% to $3.30. The company's MedSurg and Neurotechnology division posted sales of $3.6 billion, up 9.7%, with organic growth of 9.2%. Orthopaedics sales reached $3.0 billion, increasing 9.1%. Chair and CEO Kevin Lobo attributed the strong performance to recovery from a cyber incident, noting the company's resilience. Adjusted operating margin improved 170 basis points to 27.4%. Stryker expressed confidence in maintaining growth at the high end of the medical technology sector for the second half of 2026.

Yahoo Finance
Jul 1st, 2026
Stryker's joint-replacement moat edges Intuitive's premium valuation despite Q1 cyberattack

Stryker reported $6.02 billion in revenue for Q1 2026, missing the $6.33 billion consensus following a March cyberattack, whilst Intuitive Surgical beat expectations with $2.77 billion in revenue, up 23%, and earnings per share of $2.50 against a $2.11 consensus. Despite the cyberattack impact, Stryker's core businesses remained strong, with its Mako-driven orthopaedics franchise growing and its Vascular division jumping 27.5% following the Inari acquisition. The company maintained full-year guidance of 8% to 9.5% organic growth and delivered free cash flow of $415 million, up 227%. Stryker trades at approximately 22 times forward earnings compared to Intuitive Surgical's 39 times, as da Vinci procedure growth guidance steps down from 18% to roughly 15%.

INACTIVE